| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 2338-2343, Copyright © 1996 by Endocrine Society
ARTICLES |
BM Biller, ME Molitch, ML Vance, KB Cannistraro, KR Davis, JA Simons, JR Schoenfelder and A Klibanski
Neuroendocrine Unit, Massachusetts General Hospital, Boston 02114, USA.
Dopamine agonist administration is the primary therapy for macroprolactinomas, but bromocriptine is the only agent approved in the United States. Its use is limited by a high incidence of side effects, a short duration of action, and a lack of effectiveness in some patients. Cabergoline is a long-acting dopamine agonist specific for the D2 receptor that is more effective and better tolerated than bromocriptine in women with microadenomas or idiopathic hyperprolactinemia. However, experience with cabergoline in the treatment of patients with macroadenomas is limited. We report the first study of chronic administration of cabergoline conducted exclusively in patients with macroprolactinomas. Fifteen patients (8 women, 7 men) ages 18-76 yr were studied in an open-label 48-week dose escalation trial of cabergoline administered once per week. Eleven patients had received prior therapy with other dopamine agonists. Mean prolactin (PRL) levels decreased by 93.6%, and normal levels were attained in 73% of patients at doses of 0.5-3.0 mg per week. Three of five patients who had failed to normalize PRL on prior dopamine agonists achieved normal levels. Gonadal function was restored in all hypogonadal men and in 75% of premenopausal women with amenorrhea. Tumor size decreased in 11 of the 15 patients. Side effects were minimal. Of the 5 patients who had experienced side effects in prior dopamine agonists, 4 had none on cabergoline, and the fifth had milder symptoms. During two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during cabergoline administration, and three patients have experienced a further decline in PRL and/or tumor size. This study demonstrates the effectiveness and minimal side effects of once-weekly cabergoline for treatment of macroprolactinomas.
This article has been cited by other articles:
 |
|
 |
|
  M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki, O. Kubo, T. Hori, and K. Takano Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4721 - 4727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kaushik, M. R Soule, W. A Ellison, B. Ahmed, and R. Kaushik Cabergoline-Associated Erythema Nodosum Ann. Pharmacother., February 1, 2008; 42(2): 284 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Abrams, O. Alexopoulou, R. Abs, D. Maiter, and J. Verhelst Optimalization and cost management of lanreotide-Autogel therapy in acromegaly Eur. J. Endocrinol., November 1, 2007; 157(5): 571 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simon, and A. Pellicer Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2931 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shimon, C. Benbassat, and M. Hadani Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men Eur. J. Endocrinol., February 1, 2007; 156(2): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barlier and P. Jaquet Quinagolide - a valuable treatment option for hyperprolactinaemia Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, and G. Lombardi Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1704 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Rosa, S. Zarrilli, G. Vitale, C. Di Somma, F. Orio, L. Tauchmanova', G. Lombardi, and A. Colao Six Months of Treatment with Cabergoline Restores Sexual Potency in Hyperprolactinemic Males: An Open Longitudinal Study Monitoring Nocturnal Penile Tumescence J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 621 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, and G. Lombardi Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia N. Engl. J. Med., November 20, 2003; 349(21): 2023 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Gillam, S. Middler, D. J. Freed, and M. E. Molitch The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4447 - 4451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Sarno, M. L. Landi, P. Cappabianca, F. Di Salle, F. W. Rossi, R. Pivonello, C. Di Somma, A. Faggiano, G. Lombardi, and A. Colao Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5256 - 5261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J Tansey and J A Schlechte Pituitary production of prolactin and prolactin-suppressing drugs Lupus, October 1, 2001; 10(10): 660 - 664. [Abstract] [PDF]
|
|
|
|
|
|
A. Colao, A. Di Sarno, M. L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, R. Volpe, F. Di Salle, S. Cirillo, L. Annunziato, et al. Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2247 - 2252. [Abstract] [Full Text]
|
|
|
|
|
|
P. U. Freda, C. I. Andreadis, A. G. Khandji, M. Khoury, J. N. Bruce, T. P. Jacobs, and S. L. Wardlaw Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 8 - 13. [Full Text]
|
|
|
|
|
|
P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]
|
|
|
|
|
|
J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts, P. Petrossians, P. Coremans, et al. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2518 - 2522. [Abstract] [Full Text]
|
|
|
|
|
|
A. Colao, S. Loche, M. Cappa, A. Di Sarno, M. L. Landi, F. Sarnacchiaro, G. Facciolli, and G. Lombardi Prolactinomas in Children and Adolescents. Clinical Presentation and Long-Term Follow-Up J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2777 - 2780. [Abstract] [Full Text]
|
|
|
|
|
|
R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.-L. Coolens, C. Mahler, and A. Beckers Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 374 - 378. [Abstract] [Full Text]
|
|
|
|
|
|
A. Colao, A. Di Sarno, M. L. Landi, S. Cirillo, F. Sarnacchiaro, G. Facciolli, R. Pivonello, M. Cataldi, B. Merola, L. Annunziato, et al. Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3574 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Delgrange and J. Donckier Prolactinomas Apparently Resistant To Quinagolide Respond To Cabergoline Therapyb J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2755a - 2756. [Full Text]
|
|
|
|
|
|
A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, and G. Lombardi Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 876 - 883. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
